In vitro interactions of antifungal agents against clinical isolates of Fusarium spp.

被引:41
|
作者
Cordoba, Susana [1 ]
Rodero, Laura [2 ]
Vivot, Walter [1 ]
Abrantes, Ruben [1 ]
Davel, Graciela [1 ]
Vitale, Roxana G. [1 ,3 ,4 ]
机构
[1] ANLIS Dr CG Malbran, INEI, Dept Micol, Buenos Aires, DF, Argentina
[2] Univ Catol, Fac Ciencias Med, Buenos Aires, DF, Argentina
[3] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina
[4] Centraalbureau Voor Schimmelcultures, Utrecht, Netherlands
关键词
Fusarium spp; antifungal susceptibility; antifungal interactions;
D O I
10.1016/j.ijantimicag.2007.09.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The in vitro activities of amphotericin B (AMB), itraconazole (ITC), voriconazole (VCZ) and terbinafine (TBF) alone and in the combinations AMB + VCZ, TBF + ITC and TBF + VCZ were evaluated against 29 clinical isolates of Fusarium spp. (15 Fusarium solani, 7 Fusarium oxysporum, 2 Fusarium decemcellulare, 2 Fusarium dimerum and 3 other Fusarium spp.). Minimum inhibitory concentrations were determined using the method of the Clinical and Laboratory Standards Institute and the interaction activity was calculated using the fractional inhibitory concentration index. The four antifungal drugs tested alone showed very limited activity against most of the isolates. In contrast., the combination TBF + VCZ showed synergy for 21 isolates. The combination AMB + VCZ showed synergism for only five strains. No interaction or antagonism was observed among the remaining strains. TBF + ITC showed no interaction for 18 strains. The in vitro antifungal activity of the drugs alone and in combination varied for different species. These results corroborate previous in vitro studies in which the combination TBF + VCZ showed synergy against Fusarium spp., although further studies are needed to elucidate its potential usefulness for therapy. (C) 2007 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:171 / 174
页数:4
相关论文
共 50 条
  • [11] Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods
    Alastruey-Izquierdo, Ana
    Cuenca-Estrella, Manuel
    Monzon, Araceli
    Mellado, Emilia
    Luis Rodriguez-Tudela, Juan
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (04) : 805 - 809
  • [12] Antifungal activities of diphenyl diselenide and ebselen alone and in combination with antifungal agents against Fusarium spp.
    Venturini, Tarcieli Pozzebon
    Chassot, Francieli
    Loreto, Erico Silva
    Keller, Jessica Tairine
    Azevedo, Maria Izabel
    Zeni, Gilson
    Santurio, Janio Morais
    Alves, Sydney Hartz
    MEDICAL MYCOLOGY, 2016, 54 (05) : 550 - 555
  • [13] In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains
    Pujol, I
    Guarro, J
    Gene, J
    Sala, J
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 (02) : 163 - 167
  • [14] Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy
    Tortorano, Anna Maria
    Prigitano, Anna
    Dho, Giovanna
    Esposto, Maria Carmela
    Gianni, Claudia
    Grancini, Anna
    Ossi, Cristina
    Viviani, Maria Anna
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2008, 52 (07) : 2683 - 2685
  • [15] Identification and in vitro response to antifungal drugs of clinical isolates of Pithomyces spp.
    Da Cunha, K. C.
    Sutton, D. A.
    Gene, J.
    Cano, J.
    Capilla, J.
    Guarro, J.
    MYCOSES, 2013, 56 : 62 - 63
  • [16] In vitro activities of six antifungal agents and their combinations against Chaetomium spp.
    Sun, Lingyue
    Wan, Zhe
    Li, Ruoyu
    Yu, Jin
    JOURNAL OF MEDICAL MICROBIOLOGY, 2019, 68 (07) : 1042 - 1046
  • [17] IN VITRO SUSCEPTIBILITY OF Candida Spp. ISOLATED FROM CLINICAL SPECIMENS AGAINST SOME ANTIFUNGAL AGENTS
    Ozcelik, Berrin
    Balaban, Neriman
    Aksaray, Sebahat
    Cesur, Salih
    Kaynak, Fatma
    Cayirli, Altan
    TURKISH JOURNAL OF PHARMACEUTICAL SCIENCES, 2006, 3 (01) : 1 - 6
  • [18] In-vitro activity of the synthetic protegrin IB-367 alone and in combination with antifungal agents against clinical isolates of Candida spp.
    Barchiesi, F.
    Giacometti, A.
    Cirioni, O.
    Arzeni, D.
    Kamysz, W.
    Silvestri, C.
    Licci, A.
    Marigliano, A.
    Della Vittoria, A.
    Nadolski, P.
    Lukasiak, J.
    Scalise, G.
    JOURNAL OF CHEMOTHERAPY, 2007, 19 (05) : 514 - 518
  • [19] In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp.
    Marco, F
    Pfaller, MA
    Messer, S
    Jones, RN
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (01) : 161 - 163
  • [20] In vitro activity of linezolid against clinical isolates of Fusobacterium spp.
    Daeschlein, G.
    Hoehne, C.
    Assadian, O.
    Daxboeck, F.
    Meinl, C.
    Kramer, A.
    Kekule, A. S.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (04) : 789 - 793